• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Plasma D ‐dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER‐HF trial
ConclusionsIn COMMANDER-HF, rivaroxaban reduced the risk of stroke but the benefit may be confined to patients with D-dimer concentrations above 515  ng/mL. Prospective trials are warranted to confirm these findings.
Source: European Journal of Heart Failure - June 18, 2021 Category: Cardiology Authors: Jo ão Pedro Ferreira, Carolyn S.P. Lam, Stefan D. Anker, Mandeep R. Mehra, Dirk J. Veldhuisen, William M. Byra, David A. La Police, John G.F. Cleland, Barry Greenberg, Faiez Zannad Tags: Research article Source Type: research

Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction
ConclusionThe hemodynamic response to exercise was very heterogenous among patients with HFpEF, with chronotropic incompetence observed in up to 56% and 28% had impaired increase in SVI. This suggests that hemodynamic exercise testing may be useful to identify which HFpEF patients may benefit from interventions targeting stroke volume and chronotropic response.Clinical Trial RegistrationClincaltrial.gov (NCT01913613, NCT02600234, NCT01974557)
Source: European Journal of Heart Failure - March 9, 2021 Category: Cardiology Authors: Emil Wolsk, David M. Kaye, Jan Komtebedde, Sanjiv J. Shah, Barry A. Borlaug, Daniel Burkhoff, Dalane W. Kitzman, John G. Cleland, Gerd Hasenfu ß, Christian Hassager, Jacob E. Møller, Finn Gustafsson Tags: Research Article Source Type: research

Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial
ConclusionCOMMANDER HF is the first prospective study of a target‐specific oral antithrombotic agent in HF. It will provide important information regarding rivaroxaban use following an HF event in an HF‐rEF patient population with coronary artery disease.
Source: European Journal of Heart Failure - April 27, 2015 Category: Cardiology Authors: Faiez Zannad, Barry Greenberg, John G.F. Cleland, Mihai Gheorghiade, Dirk J. van Veldhuisen, Mandeep R. Mehra, William M. Byra, Min Fu, Roger M. Mills Tags: Original Article Source Type: research

Effect of Patisiran on Stroke Volume in Hereditary Transthyretin ‐Mediated Amyloidosis: Insights from Pressure‐Volume Analysis of the APOLLO Study
ConclusionsPatisiran may delay progression of LV chamber dysfunction starting at 9 months of therapy. These data elucidate the mechanisms by which transthyretin reducing therapies modulate progression of cardiac disease and need to be confirmed in ongoing phase III trials.
Source: European Journal of Heart Failure - January 25, 2023 Category: Cardiology Authors: Hannah R. Rosenblum, Jan M. Griffin, Masatoshi Minamisawa, Narayana Prasad, John Vest, Matthew T. White, Scott D. Solomon, M.D. Daniel Burkhoff, Mathew S. Maurer Tags: Research Article Source Type: research

CHA2DS2 ‐VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm
ConclusionsThe CHA2DS2‐VASc score predicted adverse outcomes in patients with systolic heart failure in sinus rhythm, with modest prediction accuracy.
Source: European Journal of Heart Failure - June 30, 2016 Category: Cardiology Authors: Siqin Ye, Min Qian, Bo Zhao, Richard Buchsbaum, Ralph L. Sacco, Bruce Levin, Marco R. Di Tullio, Douglas L. Mann, Patrick M. Pullicino, Ronald S. Freudenberger, John R. Teerlink, J.P. Mohr, Susan Graham, Arthur J. Labovitz, Conrado J. Estol, Dirk J. Lok, Tags: Short Report Source Type: research

New evidence for favourable effects on haemodynamics and ventricular performance after Parachute® implantation in humans
ConclusionThe data demonstrate the acute haemodynamic efficacy of Parachute device implantation. The implantation of the device displays immediate significant left ventricular volume reduction leading to an acute improved right and left cardiac function, proving the concept of left ventricular partitioning.
Source: European Journal of Heart Failure - October 9, 2014 Category: Cardiology Authors: Tobias Schmidt, Christian Frerker, Thomas Thielsen, Inge Dotz, Peter Wohlmuth, Karl‐Heinz Kuck, Ulrich Schäfer Tags: Original Article Source Type: research

Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study
Conclusion Underlying co-morbidities or subtle alterations such as mild left atrial dilatation or low-normal LVEF in the absence of overt underlying heart disease are baseline independent risk factors for incident HF during a long-term follow-up. Incident HF was an independent predictor of adverse outcomes in patients initially diagnosed with first-diagnosed AF and structurally normal hearts. These findings could facilitate the identification of AF patients at increased risk for adverse outcomes within the cohort perceived as being at ‘low risk’ given a structurally normal heart on echocardiography.
Source: European Journal of Heart Failure - March 22, 2013 Category: Cardiology Authors: Potpara, T. S., Polovina, M. M., Licina, M. M., Marinkovic, J. M., Lip, G. Y. H. Tags: PROGNOSIS Source Type: research

Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction
Conclusion While diastolic dysfunction promotes congestion and pulmonary hypertension with stress in HFpEF, reduction in exercise capacity is predominantly related to inadequate CO relative to metabolic needs.
Source: European Journal of Heart Failure - June 21, 2013 Category: Cardiology Authors: Abudiab, M. M., Redfield, M. M., Melenovsky, V., Olson, T. P., Kass, D. A., Johnson, B. D., Borlaug, B. A. Tags: EXERCISE PHYSIOLOGY Source Type: research

Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension
ConclusionsEven after thorough decongestion and under continuous afterload reduction, PH secondary to HFrEF is completely reversible in only a minority of patients. Others demonstrate an exercise‐induced PVR increase, associated with impaired right ventricular stroke work, which might be ameliorated by nitric oxide donor support.
Source: European Journal of Heart Failure - December 30, 2014 Category: Cardiology Authors: Frederik H. Verbrugge, Matthias Dupont, Philippe B. Bertrand, Petra Nijst, Lars Grieten, Joseph Dens, David Verhaert, Stefan Janssens, W. H. Wilson Tang, Wilfried Mullens Tags: Original Article Source Type: research

A randomised, double ‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes
ConclusionMetformin treatment in non ‐diabetic HFrEF patients improved myocardial efficiency by reducing myocardial oxygen consumption. Measurement of circulating metformin levels differentiated responders from non‐responders. These energy‐sparing effects of metformin encourage further large‐scale investigations in heart failur e patients without diabetes.
Source: European Journal of Heart Failure - December 20, 2019 Category: Cardiology Authors: Anders Hostrup Larsen, Niels Jessen, Helene N ørrelund, Lars Poulsen Tolbod, Hendrik Johannes Harms, Søren Feddersen, Flemming Nielsen, Kim Brøsen, Nils Henrik Hansson, Jørgen Frøkiær, Steen Hvitfeldt Poulsen, Jens Sörensen, Henrik Wigg Tags: Research Article Source Type: research

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
ConclusionsDanicamtiv was well tolerated and improved LV systolic function in patients with HFrEF. A marked improvement in LA volume and function was also observed in patients, consistent with pre ‐clinical findings of direct activation of LA contractility.
Source: European Journal of Heart Failure - June 18, 2020 Category: Cardiology Authors: Adriaan A. Voors, Jean ‐François Tamby, John G. Cleland, Michael Koren, Leslie B. Forgosh, Dinesh Gupta, Lars H. Lund, Albert Camacho, Ravi Karra, Henk P. Swart, Pierpaolo Pellicori, Frank Wagner, Ray E. Hershberger, Narayana Prasad, Robe Tags: Research Article Source Type: research

One ‐year results of the first‐in‐man study investigating the Atrial‐Flow‐Regulator for left‐atrial shunting in symptomatic heart failure patients: the PRELIEVE study
ConclusionsImplantation of the AFR device in HF patients was feasible. No shunt occlusion, stroke or new right HF was observed during the one ‐year follow‐up, with clinical improvements in certain patients.
Source: European Journal of Heart Failure - February 8, 2021 Category: Cardiology Authors: Christina Paitazoglou, Martin W. Bergmann, Ramazan Özdemir, Roman Pfister, Jozef Bartunek, Teoman Kilic, Alexander Lauten, Alexander Schmeisser, Mehdi Zoghi, Stefan Anker, Horst Sievert, Felix Mahfoud, AFR‐PRELIEVE Investigators Tags: Research Article Source Type: research

Pages: 1  2  3  4  5